Gene test mix-up brings scrutiny to industry
By Alejandro Martínez-Cabrera,
San Francisco Chronicle
| 06. 11. 2010
[Quotes CGS's Jesse Reynolds]
Last week, retired marketing specialist Nora Probasco called her brother with a half-serious, half-joking question: Was she adopted?
The issue came up after the 59-year-old genealogy hobbyist from Louisville, Ky., received the results of a test she took through 23andMe, a Google-backed firm that allows people to learn more about their ancestry and some medical conditions through DNA analysis.
"I was shocked," she said. "What it came down to, the way I know to read them, is that my mom is not my mom."
To her relief, it turned out to be a mistake. Last Friday, the Mountain View firm acknowledged in a post on its Web site that it mixed up the samples of 96 clients and sent them the wrong ones. The company corrected the mistake relatively quickly, but observers see the potential for similar errors that could lead individuals to make ill-informed decisions regarding their health.
The company, which was founded in 2006, said in an e-mail that the mistake occurred when a tray with 96 samples was misplaced. The company added that new procedures have been...
Related Articles
By Rhys Blakely, The Times | 06.24.2025
Scientists have created fertile mice from male genetic material alone, a breakthrough that could one day open the door to human babies who inherit their genes from two fathers.
The experiment, led by Professor Yanchang Wei at Shanghai Jiao Tong...
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...